Anterior|Siguiente

La píldora Sì miào wán, regulando la microbiota intestinal, mejora la función de la barrera intestinal en las ratas y aumenta la expresión de ABCG2 para promover la excreción de ácido úrico en el intestino

  • role： First author第一作者
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

    Shanghai University of TCM，Shanghai 201203，China

  • Email：18742556223@163.com
  • Introduction：张远，在读硕士，从事高尿酸血症及痛风的中医药诊疗研究，E-mail：18742556223@163.com
ZHANG Yuan12,  
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

    Shanghai University of TCM，Shanghai 201203，China

ZHANG Zhongyou12,  
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

    Shanghai University of TCM，Shanghai 201203，China

FENG Huilin12,  
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

    Shanghai University of TCM，Shanghai 201203，China

DUAN Lian12,  
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

WANG Lingchun1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM）， Shanghai 200052，China

  • Email：13565799291@163.com
  • Introduction：戴号，在读硕士，副主任医师，从事高尿酸血症及痛风的中医药诊疗、足踝外科研究，E-mail：13565799291@163.com
DAI Hao1*

resumen

El objetivo del estudio es investigar el efecto de la píldora Sì miào wán en la barrera intestinal y la expresión de la proteína ABCG2 (transportador de caja de unión de nucleótidos de adenina subfamilia G miembro 2) en ratas macho con hiperuricemia (HUA) y su mecanismo de acción en el tratamiento de la hiperuricemia. Métodos: Se distribuyeron aleatoriamente 40 ratas macho de la cepa SD en un grupo normal, un grupo modelo, un grupo de baja dosis de la píldora Sì miào wán (282,6 mg / kg) y un grupo de alta dosis (565,2 mg / kg), así como un grupo de control tratado con benzbromarona (4,7 mg / kg). Para inducir la hiperuricemia, se utilizó una inyección intraperitoneal (ip) de oxonato de potasio combinada con una administración gástrica (ig) continua de uricasa durante 14 días. A partir del día 15, cada grupo de medicamentos fue tratado continuamente durante 14 días. Cuatro horas después de la última dosis, se tomaron muestras de tejido, se midió el peso corporal y se analizaron los niveles de ácido úrico en sangre, así como los indicadores de la función hepática; las muestras de tejido intestinal se tiñeron con hematoxilina y eosina (HE) para observar los cambios patológicos en el epitelio de la mucosa intestinal y se evaluaron según la escala de Chiu; se midieron los niveles de factor de necrosis tumoral alfa (TNF-α), interleucina-6 (IL-6), interleucina-1β (IL-1β), lipopolisacáridos (LPS), diamina oxidasas (DAO) [...]

palabra clave

hiperuricemia; Sì miào wán; barrera intestinal; microbiota intestinal; proteína ABCG2

References

  1. 1.
    JOOSTEN L A B，CRISAN T O，BJORNSTAD P，et al.Asymptomatic hyperuricaemia：A silent activator of the innate immune system［J］.Nat Rev Rheumatol，2020，16（2）：75-86.
  2. 2.
    DALBETH N，GOSLING A L，GAFFO A，et al.Gout［J］.Lancet，2021，397（10287）：1843-1855.
  3. 3.
    DU L，ZONG Y，LI H R，et al.Hyperuricemia and its related diseases：Mechanisms and advances in therapy［J］.Sig Transduct Target Ther，2024，9（1）：212.
  4. 4.
    BUTLER F，ALGHUBAYSHI A，ROMAN Y.The epidemiology and genetics of hyperuricemia and gout across major racial groups：A literature review and population genetics secondary database analysis［J］.J Pers Med，2021，11（3）：231.
  5. 5.
    LUO J，LI T Y，NONG F X，et al.Hyperuricemic nephropathy in traditional Chinese medicine and integrated traditional Chinese and Western medicine：A review［J］.Chin J Exp Tradit Med Form，2023，29（10）：274-282.
  6. 6.
    YIN H，LIU N，CHEN J.The role of the intestine in the development of hyperuricemia［J］.Front Immunol，2022，13：845684.
  7. 7.
    WANG Z L，LI Y C，LIAO W H，et al.Gut microbiota remodeling：A promising therapeutic strategy to confront hyperuricemia and gout［J］.Front Cell Infect Microbiol，2022，12：935723.
  8. 8.
    CHE Q Y，LUO T T，SHI J H，et al.Mechanisms by which traditional Chinese medicines influence the intestinal flora and intestinal barrier［J］.Front Cell Infect Microbiol，2022，12：863779.
  9. 9.
    YANG T Y，XIN J D，ZHOU J，et al.Research progress in traditional Chinese medicine for treating hyperuricemia［J］.Changchun J Tradit Chin Med Univ，2025，41（2）：232-236.
  10. 10.
    CHEN J W.Effect of Simiaowan on intestinal uric acid excretion and intestinal ABCG2 expression in hyperuricemia rats［D］.Shanghai：Shanghai University of Traditional Chinese Medicine，2021.
  11. 11.
    HAO Z H，ZHANG Y，ZHANG Z Y，et al.Mechanism of simiaowan promoting intestinal uric acid excretion by inhibiting IL-1β/NF-κB pathway to upregulate intestinal ABCG2 expression［J］.Shanghai J Tradit Chin Med，2025，59（3）：77-84.
  12. 12.
    FENG X X，LIU Y S，RAO Z L，et al.Establishment of acute and chronic hyperuricemia models［J］.Chin J Comp Med，2020，30（1）：74-80.
  13. 13.
    LU Y P，LIU Y，HAO W，et al.Research progress on the role of pyroptosis in intestinal ischemia-reperfusion injury［J］.Chin J Clin Pharmacol Ther，2021，26（12）：1437-1443.
  14. 14.
    YU F N，YUAN L S，LOU W F，et al.Experience of ZHANG Ning's "six methods for expelling turbidity" in treating gout［J］.Jiangsu J Tradit Chin Med，2022，54（1）：37-40.
  15. 15.
    SUN P Y，QI Q，DENG T Y，et al.Research progress on Simiao formulae in treating gout and hyperuricemia［J］.Chin Arch Trad Chin Med，2025，doi：.
  16. 16.
    PAVELCOVA K，BOHATA J，PAVLIKOVA M，et al.Evaluation of the influence of genetic variants of SLC2A9 （GLUT9） and SLC22A12 （URAT1） on the development of hyperuricemia and gout［J］.J Clin Med，2020，9（8）：2510.
  17. 17.
    HORVÁTHOVÁ V，BOHATÁ J，PAVLÍKOVÁ M，et al.Interaction of the p.Q141K variant of the ABCG2 gene with clinical data and cytokine levels in primary hyperuricemia and gout［J］.J Clin Med，2019，8（11）：1965.
  18. 18.
    FAN L J，XIA Y Y，WANG Y X，et al.Gut microbiota bridges dietary nutrients and host immunity［J］.Sci China Life Sci，2023，66（11）：2466-2514.
  19. 19.
    PORTINCASA P，BONFRATE L，VACCA M，et al.Gut microbiota and short chain fatty acids：Implications in glucose homeostasis［J］.Int J Mol Sci，2022，23（3）：1105.
  20. 20.
    MINTON K.Intestinal barrier protection［J］.Nat Rev Immunol，2022，22（3）：144-145.
  21. 21.
    KUO W T，ODENWALD M A，TURNER J R，et al.Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival［J］.Ann N Y Acad Sci，2022，1514（1）：21-33.
  22. 22.
    FAN M Y，YUAN J Z，XIE H Y，et al.Mechanisms of intestinal microecology in hyperuricemia and traditional Chinese medicine intervention：A review［J］.Chin J Exp Tradit Med Form，2025，31（5）：329-338.
  23. 23.
    LYU Q，ZHOU J，WANG C，et al.A dynamics association study of gut barrier and microbiota in hyperuricemia［J］.Front Microbiol，2023，14：1287468.
  24. 24.
    GUAN L Z，LIU R X.The role of diet and gut microbiota interactions in metabolic homeostasis［J］.Adv Biol （Weinh），2023，7（9）：e2300100.
  25. 25.
    HE J，ZHANG P W，SHEN L Y，et al.Short-chain fatty acids and their association with signalling pathways in inflammation，glucose and lipid metabolism［J］.Int J Mol Sci，2020，21（17）：6356-6356.
  26. 26.
    CHEN Y W，ZHOU J H，WANG L.Role and mechanism of gut microbiota in human disease［J］.Front Cell Infect Microbiol，2021，11：625913.
  27. 27.
    MUKHERJEE T，KUMAR N，CHAWLA M，et al.The NF-κB signaling system in the immunopathogenesis of inflammatory bowel disease［J］.Sci Signal，2024，17（818）：eadh1641.
  28. 28.
    FIORE E，VAN TYNE D，GILMORE M S.Pathogenicity of enterococci［J］.Microbiol Spectr，2019，7（4）：10.
  29. 29.
    QIU P，ISHIMOTO T，FU L F，et al.The gut microbiota in inflammatory bowel disease［J］.Front Cell Infect Microbiol，2022，12：733992.
  30. 30.
    LAM S，BAI X W，SHKOPOROV A N，et al.Roles of the gut virome and mycobiome in faecal microbiota transplantation［J］.Lancet Gastroenterol Hepatol，2022，7（5）：472-484.
  31. 31.
    WU J Y，WANG K，WANG X M，et al.The role of the gut microbiome and its metabolites in metabolic diseases［J］.Protein Cell，2021，12（5）：360-373.
  32. 32.
    XU Y X，LIU L D，ZHU J Y，et al.Alistipes indistinctus-derived hippuric acid promotes intestinal urate excretion to alleviate hyperuricemia［J］.Cell Host Microbe，2024，32（3）：366-381.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website